Momenta Shelves Adalimumab But Persists With Aflibercept
Having failed to find a commercial partner, Momenta has halted development on its adalimumab biosimilar. But it is continuing to work on biosimilar aflibercept in conjunction with partner Mylan.
You may also be interested in...
Momenta Pharmaceuticals has signed an agreement to be acquired by Johnson & Johnson, with the deal to include, for now, the M710 biosimilar aflibercept candidate being developed with Mylan.
Mylan’s Hulio has become the sixth biosimilar version of Humira to be approved by the US FDA. However, all of these adalimumab biosimilars face a wait until 2023 before they can enter the market.
Having largely shelved the firms' global biosimilars collaboration that kicked off early in 2016, Momenta and Mylan are still working towards bringing a biosimilar to the Eylea blockbuster to the US, which currently has a market worth valued at more than $4.5bn.